Abstract
The lack of sex-specific cardiovascular disease criteria contributes to the under-diagnosis of women compared to men. For more than half a century, the Framingham Risk Score has been the gold standard to estimate an individual’s risk of developing cardiovascular disease based on age, sex, cholesterol levels, blood pressure, diabetes, and smoking. Now, machine learning can offer a much more nuanced insight into predicting the risk of cardiovascular disease. The UK Biobank is a large database that includes traditional risk factors as well as tests related to the cardiovascular system: magnetic resonance imaging, pulse wave analysis, electrocardiograms, and carotid ultrasounds. Here we leverage 20,542 datasets from the UK Biobank to build more accurate cardiovascular risk models than the Framingham Risk Score, and quantify the under-diagnosis of women compared to men. Strikingly, for first-degree atrioventricular block and dilated cardiomyopathy, two conditions with non-sex-specific diagnostic criteria, our study shows that women are under-diagnosed 2x and 1.4x more than men. Similarly, our results demonstrate the need for sex-specific criteria in essential primary hypertension and hypertrophic cardiomyopathy. Our feature importance analysis reveals that, out of the top 10 features across three sex and four disease categories, traditional Framingham factors made up between 40-50%, electrocardiogram 30-33%, pulse wave analysis 13-23%, and magnetic resonance imaging and carotid ultrasound 0-10%. Improving the Framingham Risk Score by leveraging big data and machine learning allows us to incorporate a wider range of biomedical data and prediction features, enhance personalization and accuracy, and continuously integrate new data and knowledge, with the ultimate goal to improve accurate prediction, early detection, and early intervention in cardiovascular disease management.
Our analysis pipeline and trained classifiers are freely available at https://github.com/LivingMatterLab/CardiovascularDiseaseClassification
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://github.com/LivingMatterLab/CardiovascularDiseaseClassification
Funding Statement
This project was supported by an NSF Graduate Research Fellowship to SS, and by the NSF CMMI grants 2318188 and 2320933 and to EK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was conducted using the October 2022 release of the UK Biobank Resource under Application Number 89726. It uses data provided by patients and collected by the National Health Service England as part of their care and support; copyright 2022 National Health Service England; re-used with the permission of the UK Biobank; all rights reserved.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Update of the acknowledgements by request of the UK Biobank from previously "This research was conducted using the UK Biobank Resource under Application Number 89726. The data used were pulled from the October 2022 release of the UK Biobank database." to now: "This research was conducted using the October 2022 release of the UK Biobank Resource under Application Number 89726. It uses data provided by patients and collected by the National Health Service England as part of their care and support; copyright 2022 National Health Service England; re-used with the permission of the UK Biobank; all rights reserved."
Data Availability
All data produced in the present work are contained in the manuscript are available on request
